This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of investigation results Itraconazole

January 12, 2016

Non-proprietary name

Itraconazole

Brand name (Marketing authorization holder)

- a. Itrizole Capsules 50 mg (Janssen Pharmaceutical K.K.), and the others
- b. Itrizole Oral Solution 1% (Janssen Pharmaceutical K.K.)
- c. Itrizole Injections 1% (Janssen Pharmaceutical K.K.)

Indications

Refer to the attachment below.

Summary of revision

"Interstitial pneumonia" should be newly added in the Clinically significant adverse reaction section.

Background of the revision and investigation results

Cases of interstitial pneumonia have been reported in patients treated with itraconazole in Japan. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

The number of reported adverse reaction and fatal cases in the last 3 fiscal years in Japan

A total of 2 cases associated with interstitial pneumonia have been reported (including 1 case for which a causal relationship to the product could not be ruled out; however, this case was for a condition not included in the approved dosage and administration). No fatality has been reported.



Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Attachment

	Attachment		
Brand name	Indication		
a. Itrizole Capsules	<applicable microorganisms=""></applicable>		
50	Dermatophytosis (genus <i>Trichophyton</i> , genus <i>Microsporum</i> , genus		
	Epidermophyton), genus Candida, genus Malassezia, genus		
	Aspergillus, genus Cryptococcus, genus Sporothrix, and genus		
	Fonsecaea.		
	<applicable conditions=""></applicable>		
	Visceral mycosis (deep mycosis) Fungaemia, respiratory		
	mycosis, gastrointestinal mycosis, urinary tract mycosis, and		
	fungal meningitis.		
	Deep cutaneous mycosis Sporotrichosis and		
	chromomycosis		
	Superficial cutaneous mycosis (excluding nail tinea)		
	Tinea		
	Body tinea, tinea cruris, tinea manuum, tinea pedis, tinea		
	capitis, kerion Celsi, and tinea barbae.		
	Candidiasis		
	Oral candidiasis, skin candida, nail candida, candidal		
	paronychia/onychia, candidal sycosis, and chronic		
	mucocutaneous candidiasis.		
	Tinea verisicolour and Malassezia folliculitis		
	4. Nail tinea		
b. Itrizole Oral	1. Fungal infection		
Solution 1%	<applicable microorganisms=""></applicable>		
	Genus Aspergillus, genus Candida, genus Cryptococcus,		
	genus Blastomyces, and genus Histoplasma.		
	<applicable conditions=""></applicable>		
	Fungaemia, respiratory mycosis, gastrointestinal mycosis,		
	urinary tract mycosis, fungal meningitis, oropharyngeal		
	candidiasis, oesophageal candidiasis, blastomycosis, and		
	histoplasmosis.		
	2. Febrile neutropenia suspected to be caused by fungal infection		
	3. Prophylaxis for deep mycosis among patients with		
	hematological malignancies or hematopoietic stem cell		
	transplant patients predicted to develop neutropenia		



Pharmaceuticals and Medical Devices Agency

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

c. Itrizole Injection 1%	1.	Fungal infection
,		<applicable microorganisms=""></applicable>
		Genus Aspergillus, genus Candida, genus Cryptococcus,
		genus Blastomyces, and genus Histoplasma.
		<applicable conditions=""></applicable>
		Fungaemia, respiratory mycosis, gastrointestinal mycosis,
		urinary tract mycosis, fungal meningitis, oesophageal
		candidiasis, blastomycosis, and histoplasmosis.
	2.	Febrile neutropenia suspected to be caused by fungal
		infection